JP Morgan initiates coverage on Relay Therapeutics with Overweight rating
JP Morgan analyst Priyanka Grover initiated coverage on Relay Therapeutics with an Overweight rating and a price target of $28, signaling a positive outlook for the stock.
*this image is generated using AI for illustrative purposes only.
JP Morgan analyst Priyanka Grover has initiated coverage on Relay Therapeutics with an Overweight rating and a price target of $28. The rating suggests a positive outlook on the company's stock performance.
Coverage Details
The initiation of coverage highlights JP Morgan's perspective on Relay Therapeutics' potential in the market. The Overweight rating indicates that the firm expects the stock to outperform the average return of the stocks covered by its analysts.
Price Target
JP Morgan set a price target of $28 for Relay Therapeutics, providing a specific benchmark for investors. This target reflects the firm's valuation of the company's future growth prospects.
| Metric | Value |
|---|---|
| Rating | Overweight |
| Price Target | $28 |
| Analyst | Priyanka Grover |
| Coverage Firm | JP Morgan |
What specific clinical milestones or data releases could drive Relay Therapeutics' stock toward the $28 price target?
How might Relay Therapeutics' competitive landscape evolve in the coming months, and what impact could this have on its market position?
What are the potential risks or challenges that could hinder Relay Therapeutics from achieving the projected growth outlined by JP Morgan?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
